[Ototoxicity of cisplatin chemotherapy in patients with ovarian cancer].
Beck
E
E
Universitäts-Frauenklinik Erlangen.
Schuster
M
M
Berg
A
A
Jäger
W
W
Wildt
L
L
Lang
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects
C018404:treosulfan; D002066:Busulfan; D002945:Cisplatin
Ototoxizität unter cisplatin-haltiger Chemotherapie bei Patientinnen mit Ovarialkarzinomen.